Selank (N-Acetyl Selank)
The Ground Truth Score
four plain questions, never one numberReal Russian human trials, but small, unblinded, and never placebo-controlled
Bottom line
Selank has more genuine human clinical data than almost any gray-market peptide, yet every trial is small, Russian-language, and active-comparator rather than placebo-controlled, so the anxiolytic signal is plausible but unproven by Western standards.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported (not prescribed) protocols are almost exclusively intranasal, typically ~250-300 mcg up to a few hundred mcg per dose, often given 1-3 times daily, frequently in short cycles of a few weeks.
Reported, not prescribed. Verify your vial and your math.
First documented human use
First documented human clinical use traces to Russian trials in the 1990s-2000s at the V.V. Zakusov Research Institute of Pharmacology (Moscow); the earliest PubMed-indexed human anxiety trial is 2008 (n=62, selank vs the benzodiazepine medazepam in generalized anxiety disorder and neurasthenia). Important caveat: NO double-blind, placebo-controlled randomized trial of Selank has ever been completed or indexed, all published human trials are open-label or active-comparator designs, and there are no Selank-specific registrations on ClinicalTrials.gov.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- A heptapeptide analog of the immune peptide tuftsin (sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro), developed in Russia and used there as a prescription anxiolytic.
- Reported to reduce anxiety with a 'calm but clear-headed' quality, without the sedation, muscle relaxation, or dependence of benzodiazepines.
- Small Russian trials found anxiety reduction broadly comparable to benzodiazepines (medazepam, phenazepam) on rating scales.
- Commonly stacked with Semax and used off-label as a nootropic for focus and stress resilience.
- Administered intranasally because its plasma half-life is only minutes; the nose-to-brain route is the workaround.
The data behind each bullet
What actually backs it
At least three small human clinical trials in Russia tested Selank for generalized anxiety disorder/neurasthenia, reporting anxiety reduction comparable to benzodiazepines without sedative or muscle-relaxant effects.
Multiple PubMed-indexed clinical trials in the Russian journal Zh Nevrol Psikhiatr Im S S Korsakova: 2008 (n=62, vs medazepam), 2014 (n=60, vs phenazepam), 2015 (augmentation of phenazepam). All small, single-region, active-comparator; none placebo-controlled.
PubMed: selank anxiety trials ↗No double-blind, placebo-controlled randomized trial of Selank exists in the indexed literature.
A PubMed search for 'selank placebo double-blind' returns zero results; published human trials are open-label or active-comparator. This absence is the single most important fact about the evidence base.
PubMed: selank placebo double-blind (0 results) ↗There are no Selank-specific trials registered on ClinicalTrials.gov.
ClinicalTrials.gov keyword search surfaces only incidental co-occurrence matches (e.g., unrelated brivaracetam/epilepsy studies), not any trial of Selank itself.
ClinicalTrials.gov: selank ↗Selank is a synthetic analog of tuftsin, extended with a C-terminal Pro-Gly-Pro to improve metabolic stability; assumed mechanisms include modulation of GABAergic/serotonergic tone, BDNF expression, and inhibition of enkephalin-degrading enzymes.
Mechanistic claims rest largely on animal and in-vitro work plus mechanistic reviews; the human trials did not establish mechanism. Sequence/derivation are well established.
PubMed: selank (mechanism/preclinical) ↗A small human neuroimaging study (n~52 healthy participants) examined functional-connectivity effects of Selank and Semax.
A 2020 PubMed-indexed functional connectomic study in healthy volunteers; observational imaging endpoint, not a clinical efficacy RCT.
PubMed: selank connectomic 2020 ↗Selank is not FDA-approved; it was removed from FDA's interim 503A Category 2 bulks list effective Sept 27, 2024, and is sold in the US as a 'research chemical.' It is a registered prescription drug in Russia.
FDA 503A bulks-list action and regulatory reporting; Russian/CIS pharmacy availability widely documented. Regulatory facts, not efficacy.
FDA / DailyMed search: selank ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed/theoretical. Selank is a synthetic heptapeptide analog of the endogenous immune peptide tuftsin (Thr-Lys-Pro-Arg), extended with Pro-Gly-Pro to slow enzymatic breakdown. Its proposed anxiolytic/nootropic action is attributed to modulation of GABAergic and monoaminergic (serotonin/dopamine) signaling, changes in BDNF expression, and inhibition of enkephalin-degrading enzymes (raising endogenous enkephalin tone), alongside immunomodulatory effects on cytokines such as IL-6. None of these mechanisms is confirmed in controlled human studies; treat them as hypotheses carried over from animal/in-vitro work.
Dosing & handling
What users and clinicians report
Reported (not prescribed) protocols are almost exclusively intranasal, typically ~250-300 mcg up to a few hundred mcg per dose, often given 1-3 times daily, frequently in short cycles of a few weeks. The 300 mcg intranasal dose echoes the dose used in Russian GAD studies. Subcutaneous use is occasionally reported but less common. These are community/forum conventions, not validated regimens.
All dosing here is what users and vendors REPORT, not a recommendation. Because there is no FDA-approved product, there is no authoritative dose, no standardized concentration, and no quality assurance; vial-to-vial potency on the research-chemical market is unverified. Anyone considering it should do so only with a qualified clinician and a compounding pharmacy, not from gray-market suppliers.
Timing & food
Typically dosed intranasally in the morning and/or earlier in the day, with additional daytime doses if used 2-3x/day, because users want the 'calm focus' during waking hours and the effect window is only a few hours per dose. Food/fasted status is largely irrelevant for an intranasal peptide (it bypasses the gut), so timing is driven by desired daytime coverage and the short duration of action rather than meals. Late dosing is sometimes avoided by users who find it mildly activating.
Half-life
Very short in plasma, reported on the order of only a few minutes (commonly cited as roughly 2-3 minutes, with some sources citing under 2 minutes) due to rapid peptidase degradation. This is precisely why dosing is intranasal: the nose-to-brain (olfactory/trigeminal) route delivers peptide to the CNS before systemic enzymes clear it. Subjective CNS effects are anecdotally reported to last several hours per dose, but that duration is not a measured plasma half-life.
Reconstitution sensitivity
Supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. Handle as a fragile peptide: keep lyophilized vials cold/frozen until use, refrigerate after reconstitution, and protect from heat, light, and repeated freeze-thaw. Reconstituted solution is anecdotally reported stable for a few weeks refrigerated; bacteriostatic water itself has a limited (~28-day) in-use window. Do not use if powder shows moisture, yellowing, or fails to fully dissolve. Each reconstitution introduces contamination risk, especially for an intranasal product.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate. Selank has a sizable, long-running footprint in nootropic and biohacker communities (often discussed alongside Semax), more than most obscure peptides but far less than mainstream supplements, a steady stream of forum reports and reviews rather than a flood.
Consistency
Reasonably consistent in direction: most positive reports describe a subtle 'takes the edge off,' calmer-but-clear, slightly improved focus effect rather than anything dramatic. A meaningful minority report little or no effect and openly wonder whether it is placebo. Few report strong or unpleasant effects, which fits the gentle profile but also fits a weak-signal compound.
Source credibility
Mixed and to be discounted. Much of the online content is published by peptide vendors and affiliate sites with a financial interest, which inflates apparent enthusiasm; independent user anecdotes are genuine but subjective and prone to expectancy bias. The credible end of the signal is the small body of Russian clinical reports, not the forum chatter.
- Many users describe a mild, takes-the-edge-off calm without sedation, 'quieter mental chatter' and feeling less reactive to stress while staying clear-headed and able to work (anecdote, not proof).
- A common theme is that it is subtle and stacks well with Semax; people often credit the Semax+Selank combo for focus and calm, which makes Selank's individual contribution hard to isolate (anecdote).
- A notable minority report feeling little or nothing and explicitly question whether their response is placebo, sometimes after a single short cycle (anecdote).
- Users generally report it as well tolerated, with the most frequent complaint being nasal/sinus irritation or a mild headache from the intranasal spray rather than any systemic effect (anecdote).
Placebo risk, High
Every primary endpoint that users and trials care about, anxiety level, sense of calm, focus, mood, is subjective and self-reported, with no objective biomarker that an end-user can measure. Combined with strong expectancy (an exotic 'Russian anti-anxiety peptide'), frequent stacking with Semax, and the complete absence of any double-blind placebo-controlled human trial, the risk that perceived benefit is substantially placebo is high.
Risk panel
What could go wrong
Adverse events
In the small published Russian trials, adverse events were mild and transient, most commonly local nasal/sinus irritation and headache from the intranasal route, occasionally fatigue or dizziness. No serious adverse events were reported in the published trials, and unlike benzodiazepines no sedation, psychomotor impairment, dependence, or withdrawal was described.
Theoretical concerns
As a peptide that may modulate serotonergic, GABAergic and enkephalin/opioid-related signaling, theoretical interactions with SSRIs, benzodiazepines, or other CNS-active drugs cannot be excluded, though none are well characterized. As an immunomodulatory tuftsin analog it could in theory influence cytokine/immune tone (IL-6, T-helper balance), with unknown clinical relevance.
Contraindications
No formally established contraindications because no Western regulatory label exists. There is explicitly NO human safety data in pregnancy, lactation, or childhood, and Russian study protocols excluded participants under 18; these groups should be treated as contraindicated by default. US 'research chemical' supply carries purity, sterility, and mislabeling risk independent of the molecule itself.
Honest unknowns
No long-term human safety data, no Western pharmacovigilance, and no large or placebo-controlled trials. Real-world purity/dose accuracy of gray-market vials is unverified. Whether intranasal self-dosing reproduces the pharmacology seen in supervised Russian trials is unknown. Effect sizes versus true placebo are entirely uncharacterized.
Confound watch
Selank is very commonly co-administered with Semax (and sometimes with SSRIs, phenibut, caffeine, or other nootropics), which makes it nearly impossible for users to attribute any calm-focus effect to Selank specifically. Concurrent therapy, exercise, sleep changes, and the strong subjective expectancy around 'a Russian anti-anxiety peptide' all muddy attribution.
History
Discovery → first use → status
- 1990sDeveloped at the Institute of Molecular Genetics, Russian Academy of Sciences, by extending the immune peptide tuftsin (Thr-Lys-Pro-Arg) with Pro-Gly-Pro for metabolic stability; clinical development with the V.V. Zakusov Research Institute of Pharmacology.
- 2008Earliest PubMed-indexed human anxiety trial (n=62): Selank vs medazepam in GAD and neurasthenia, reporting comparable anxiolytic effect without sedation.
- 2014Comparative clinical trial (n=60) of Selank vs phenazepam in phobic-anxiety disorders published in the Korsakov journal.
- 2015Trial of Selank as augmentation to phenazepam monotherapy for anxiety disorders.
- 2020Functional-connectomic neuroimaging study of Selank and Semax in ~52 healthy participants.
- 2024-09-27FDA removed Selank acetate from Category 2 of the interim 503A bulks list (following nominator withdrawal); remains unapproved and US-marketed as research-only.
Verification
The COA standard, applied
Cross-checked against PubMed (confirmed real human clinical trials exist: 2008 n=62 vs medazepam, 2014 n=60 vs phenazepam, 2015 augmentation, plus a 2020 imaging study, all small, Russian, none placebo-controlled), a PubMed search confirming zero double-blind placebo-controlled trials, ClinicalTrials.gov (no Selank-specific registrations, only incidental keyword matches), Wikipedia (sequence/tuftsin derivation/Institute of Molecular Genetics origin), and FDA 503A bulks-list reporting (removed from Category 2 effective 2024-09-27). Vendor-page statistics such as a precise '47% vs 34% placebo' figure could NOT be tied to any indexed placebo-controlled trial and were therefore treated as unverified and excluded.
The full verification standard →Sources
Where this comes from
- PubMed, selank anxiety (human trials) ↗· Confirms small Russian clinical trials (2008 n=62 vs medazepam; 2014 n=60 vs phenazepam; 2015 augmentation). Active-comparator, not placebo-controlled.
- PubMed, selank placebo double-blind (0 results) ↗· Returns zero results, no double-blind, placebo-controlled trial is indexed.
- PubMed, selank (full literature) ↗· ~135 results, predominantly animal/in-vitro/mechanistic plus a few small human studies.
- ClinicalTrials.gov, selank ↗· No Selank-specific registered trials; only incidental keyword co-occurrence matches.
- DailyMed/FDA, selank search ↗· No FDA-approved labeling; confirms unapproved status in the US.
- Wikipedia. Selank ↗· Sequence (TKPRPGP), tuftsin derivation, Institute of Molecular Genetics origin, Russian/Ukrainian pharmacy availability.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.